bluebird bio to Independently Invest in and Pursue a Broad T cell-Based Immuno-oncology Strategy
Investor Conference Call Scheduled for
Under the terms of the amended and restated collaboration agreement:
-
bluebird bio will receive a
$25 million payment to develop the lead anti-BCMA product candidate through a Phase 1 clinical trial and develop next-generation anti-BCMA product candidates. - bluebird bio will be responsible for the development of all anti-BCMA product candidates through the completion of Phase 1 studies.
-
Additionally, on a product-by-product basis within the anti-BCMA
product program,
Celgene has an option to develop and commercialize each product candidate worldwide, and bluebird bio has the option to share equally in the development, promotion and profits of each product candidate inthe United States . In addition to the payments described above and consistent with the prior agreement,Celgene would also pay bluebird bio specified development and regulatory milestone payments as well as royalty payments on net sales.
“We have successfully achieved the initial goal of our collaboration
with
“Our collaboration with bluebird bio has collectively made strong
progress advancing a lead product candidate, targeting BCMA, toward the
clinic in hematologic malignancies. We look forward to continuing to
work with bluebird and build on the recent success to advance the
anti-BCMA program and ultimately, to succeed on the goal of delivering a
high-impact therapeutic in the CAR T arena,” said
A Unique Position in Immuno-oncology
Outside of BCMA,
bluebird bio is independently pursuing the development of a broad
portfolio of novel immuno-oncology therapeutics. This portfolio will
leverage bluebird bio technology, including its lentiviral vector
platform, gene editing capabilities and internal gene therapy and
immuno-oncology expertise.
“Consistent with the long-term vision for bluebird bio, we are expanding
our immuno-oncology T cell-based efforts in parallel with our late-stage
hematopoietic stem cell-based programs,” said
Currently, bluebird bio has active pre-clinical research programs
targeting multiple different, novel oncology antigens, including BCMA.
These programs include various T cell therapies with significant
academic and industry collaborations. bluebird bio recently announced a
strategic collaboration with
Investor Conference Call and Webcast Information
bluebird
bio will host a conference call and webcast at
About bluebird bio, Inc.
With its lentiviral-based gene
therapy and gene editing capabilities, bluebird bio has built an
integrated product platform with broad potential application to severe
genetic diseases and T cell-based immunotherapy. bluebird bio’s clinical
programs include Lenti-D™, currently in a Phase 2/3 study, called the
Starbeam Study, for the treatment of childhood cerebral
adrenoleukodystrophy, and LentiGlobin®, currently in three
clinical studies: a global Phase 1/2 study, called the Northstar Study,
for the treatment of beta-thalassemia major; a single-center Phase 1/2
study in France (HGB-205) for the treatment of beta-thalassemia major or
severe sickle cell disease; and a separate U.S. Phase 1 study for the
treatment of sickle cell disease (HGB-206). bluebird bio also has
ongoing preclinical CAR T immuno-oncology programs, as well as discovery
research programs utilizing megaTALs/homing endonuclease gene editing
technologies.
bluebird bio has operations in Cambridge, Massachusetts, Seattle,
Forward-Looking Statements
This release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements regarding
the research, development and advancement of bluebird bio's
immuno-oncology product candidates and CAR T research programs. Any
forward-looking statements are based on management’s current
expectations of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and
adversely from those set forth in or implied by such forward-looking
statements. These risks and uncertainties include, but are not limited
to, the risk that bluebird bio's immuno-oncology research programs will
be unsuccessful and not identify any viable product candidates or will
not be safe or effective in clinical trials, the risk of cessation or
delay of any of the planned clinical studies and/or our development of
our immuno-oncology product candidates, the risk of a delay in the
enrollment of patients in the Company’s clinical studies, the risk that
our collaboration with
Availability of other information about bluebird bio
Investors
and others should note that we communicate with our investors and the
public using our company website (www.bluebirdbio.com),
our investor relations website (http://www.bluebirdbio.com/investor-splash.html),
including but not limited to investor presentations and FAQs,
View source version on businesswire.com: http://www.businesswire.com/news/home/20150603006527/en/
Source: bluebird bio, Inc.
Investor Relations:
bluebird bio, Inc.
Manisha Pai,
617-245-2107
mpai@bluebirdbio.com
or
Media:
Pure
Communications
Dan Budwick, 973-271-6085